Indolent non-Hodgkin B-cell lymphoma
Conditions
Interventions
case series:NA
Sponsors
Harbin First Hospital/ Peking University Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-75 years, diagnosed as CD20-positive Indolent non-Hodgkin B-cell lymphoma (containing follicular lymphoma of grade 1-3a, waldenstrom macroglobulinemia, marginal zone lymphoma,chronic lymphocytic leukemia/small lymphocytic lymphoma); 2. Patients had not been previously treated for indolent lymphoma; 3. Patients who could benefit from bendamustine treatment assessed by doctors, treatment regimens containing bendamustine include the following four combinations: (1) Bendamustine (2) Bendamustine + rituximab (3) Bendamustine + rituximab + cytarabine (4) Bendamustine + rituximab + bortezomib; 4. Patients volunteered to participate in the study and signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients who are known to be allergic to any drug in the treatment plan or have metabolic disorders; 2. Patients with central nervous system lymphoma or pial lymphoma; 3. The objects who refuse to take reliable contraceptive methods during pregnancy, lactation or school age; 4. Patients with any uncontrollable medical diseases (including uncontrolled diabetes, severe heart, lung, liver and kidney dysfunction (CrCl < 30ml / min, AST / ALT or total bilirubin more than 3 times ULN)) and history of blood, endocrine system diseases and other malignant tumors; 5. Patients with serious mental illness; 6. Patients considered unsuitable by researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| complete response rate;partial response rate;1 year PFS (progress free survival);safety; | — |
Countries
China
Contacts
Public ContactJun Ma/Jun Zhu
Harbin First Hospital/ Peking University Cancer Hospital
Outcome results
None listed